{"id":"https://openalex.org/W2891364583","doi":"https://doi.org/10.1136/annrheumdis-2017-212916","title":"Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus","display_name":"Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus","publication_year":2018,"publication_date":"2018-10-01","ids":{"openalex":"https://openalex.org/W2891364583","doi":"https://doi.org/10.1136/annrheumdis-2017-212916","mag":"2891364583","pmid":"https://pubmed.ncbi.nlm.nih.gov/29945920","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6161670"},"language":"en","primary_location":{"id":"doi:10.1136/annrheumdis-2017-212916","doi":"https://doi.org/10.1136/annrheumdis-2017-212916","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2017-212916","pdf_url":"https://ard.bmj.com/content/annrheumdis/77/10/1516.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://ard.bmj.com/content/annrheumdis/77/10/1516.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102815745","display_name":"Peter H Schafer","orcid":"https://orcid.org/0000-0002-3880-0850","observed_orcids":["https://orcid.org/0000-0002-3880-0850"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Peter H Schafer","raw_affiliation_strings":["Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA","Department of Translational Development, Celgene Corporation, Summit, NJ 07901, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I4387155837"]},{"raw_affiliation_string":"Department of Translational Development, Celgene Corporation, Summit, NJ 07901, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100362696","display_name":"Ying Ye","orcid":"https://orcid.org/0000-0002-1911-0731","observed_orcids":["https://orcid.org/0000-0002-1911-0731"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ying Ye","raw_affiliation_strings":["Department of Clinical Pharmacology, Celgene Corporation, Summit, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, Celgene Corporation, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050832925","display_name":"Lei Wu","orcid":"https://orcid.org/0000-0002-8556-0343","observed_orcids":["https://orcid.org/0000-0002-8556-0343"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lei Wu","raw_affiliation_strings":["Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078233258","display_name":"Jolanta Kosek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jolanta Kosek","raw_affiliation_strings":["Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007459007","display_name":"Garth E. Ringheim","orcid":"https://orcid.org/0000-0002-9026-2674","observed_orcids":["https://orcid.org/0000-0002-9026-2674"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Garth Ringheim","raw_affiliation_strings":["Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Zhihong Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhihong Yang","raw_affiliation_strings":["Department of Biostatistics, Celgene Corporation, Summit, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, Celgene Corporation, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044095153","display_name":"Liangang Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liangang Liu","raw_affiliation_strings":["Department of Biostatistics, Celgene Corporation, Summit, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, Celgene Corporation, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034621627","display_name":"Michael A. Thomas","orcid":"https://orcid.org/0000-0003-2982-0291","observed_orcids":["https://orcid.org/0000-0003-2982-0291"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Thomas","raw_affiliation_strings":["Department of Clinical Pharmacology, Celgene Corporation, Summit, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, Celgene Corporation, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042912939","display_name":"Maria Palmisano","orcid":"https://orcid.org/0000-0003-1518-5688","observed_orcids":["https://orcid.org/0000-0003-1518-5688"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria Palmisano","raw_affiliation_strings":["Department of Clinical Pharmacology, Celgene Corporation, Summit, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, Celgene Corporation, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111591940","display_name":"Rajesh Chopra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Rajesh Chopra","raw_affiliation_strings":["Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA","Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I4387155837"]},{"raw_affiliation_string":"Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK","institution_ids":["https://openalex.org/I142947616"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5102815745"],"corresponding_institution_ids":["https://openalex.org/I4387155837"],"apc_list":{"value":4870,"currency":"USD","value_usd":4870},"apc_paid":{"value":4870,"currency":"USD","value_usd":4870},"fwci":6.5166,"has_fulltext":true,"cited_by_count":78,"citation_normalized_percentile":{"value":0.97659067,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"77","issue":"10","first_page":"1516","last_page":"1523"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10308","display_name":"Systemic Lupus Erythematosus Research","score":0.9609000086784363,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10308","display_name":"Systemic Lupus Erythematosus Research","score":0.9609000086784363,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0340999998152256,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13026","display_name":"Natural Compounds in Disease Treatment","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2707","display_name":"Complementary and alternative medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/iberdomide","display_name":"iberdomide","score":0.9520000219345093},{"id":"https://openalex.org/keywords/ikaros","display_name":"Ikaros","score":0.8790000081062317},{"id":"https://openalex.org/keywords/aiolos","display_name":"Aiolos","score":0.9769999980926514},{"id":"https://openalex.org/keywords/ikzf1","display_name":"IKZF1","score":0.9810000061988831},{"id":"https://openalex.org/keywords/ikzf3","display_name":"IKZF3","score":0.9990000128746033},{"id":"https://openalex.org/keywords/systemic-lupus-erythematosus","display_name":"systemic lupus erythematosus","score":0.9909999966621399},{"id":"https://openalex.org/keywords/immunomodulation","display_name":"immunomodulation","score":0.734000027179718},{"id":"https://openalex.org/keywords/autoantibody-production","display_name":"autoantibody production","score":0.7889999747276306},{"id":"https://openalex.org/keywords/anti-dsdna-antibodies","display_name":"anti-dsDNA antibodies","score":0.8349999785423279},{"id":"https://openalex.org/keywords/antiphospholipid-antibodies","display_name":"antiphospholipid antibodies","score":0.972000002861023},{"id":"https://openalex.org/keywords/b-cells","display_name":"B cells","score":0.656000018119812},{"id":"https://openalex.org/keywords/t-cells","display_name":"T cells","score":0.9129999876022339},{"id":"https://openalex.org/keywords/monocytes","display_name":"monocytes","score":0.7400000095367432},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.8009999990463257},{"id":"https://openalex.org/keywords/interleukin-1beta","display_name":"IL-1\u03b2","score":0.8880000114440918},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7310000061988831},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.453000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8997286558151245},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5583798885345459}],"mesh":[{"descriptor_ui":"D001323","descriptor_name":"Autoantibodies","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D001323","descriptor_name":"Autoantibodies","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005434","descriptor_name":"Flow Cytometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006576","descriptor_name":"Heterocyclic Compounds, 4 or More Rings","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008180","descriptor_name":"Lupus Erythematosus, Systemic","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008180","descriptor_name":"Lupus Erythematosus, Systemic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008180","descriptor_name":"Lupus Erythematosus, Systemic","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D009025","descriptor_name":"Morpholines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010447","descriptor_name":"Peptide Hydrolases","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D010447","descriptor_name":"Peptide Hydrolases","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D010797","descriptor_name":"Phthalimides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010881","descriptor_name":"Piperidones","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015153","descriptor_name":"Blotting, Western","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D044767","descriptor_name":"Ubiquitin-Protein Ligases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D048868","descriptor_name":"Adaptor Proteins, Signal Transducing","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051740","descriptor_name":"Ikaros Transcription Factor","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D051740","descriptor_name":"Ikaros Transcription Factor","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D056747","descriptor_name":"Immunomodulation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1136/annrheumdis-2017-212916","doi":"https://doi.org/10.1136/annrheumdis-2017-212916","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2017-212916","pdf_url":"https://ard.bmj.com/content/annrheumdis/77/10/1516.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5112904","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC6161670","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6161670","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6161670","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ann Rheum Dis","raw_type":"Text"},{"id":"pmid:29945920","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29945920","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the rheumatic diseases","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:open-archive.highwire.org:annrheumdis:77/10/1516","doi":null,"is_oa":false,"landing_page_url":"http://ard.bmj.com/cgi/content/short/77/10/1516","pdf_url":null,"source":{"id":"https://openalex.org/S4406923041","display_name":"HighWire Press Open Archive","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"TEXT"}],"best_oa_location":{"id":"doi:10.1136/annrheumdis-2017-212916","doi":"https://doi.org/10.1136/annrheumdis-2017-212916","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2017-212916","pdf_url":"https://ard.bmj.com/content/annrheumdis/77/10/1516.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G3601372966","display_name":null,"funder_award_id":"11566","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G662952953","display_name":null,"funder_award_id":"22897","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"}],"funders":[{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320319985","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2891364583.pdf","grobid_xml":"https://content.openalex.org/works/W2891364583.grobid-xml"},"referenced_works_count":23,"referenced_works":["https://openalex.org/W1624447595","https://openalex.org/W1879002358","https://openalex.org/W1971833707","https://openalex.org/W1973999018","https://openalex.org/W1997952190","https://openalex.org/W2021740276","https://openalex.org/W2028622220","https://openalex.org/W2029255228","https://openalex.org/W2031580483","https://openalex.org/W2036209857","https://openalex.org/W2051569082","https://openalex.org/W2052360985","https://openalex.org/W2066713758","https://openalex.org/W2068412287","https://openalex.org/W2084778320","https://openalex.org/W2104380023","https://openalex.org/W2115859409","https://openalex.org/W2125477622","https://openalex.org/W2135199713","https://openalex.org/W2148717156","https://openalex.org/W2170293791","https://openalex.org/W2606131188","https://openalex.org/W2752652435"],"related_works":["https://openalex.org/W3138604854","https://openalex.org/W4225105825","https://openalex.org/W4224880003","https://openalex.org/W4213290980","https://openalex.org/W4220657516","https://openalex.org/W2939113095","https://openalex.org/W2952157089","https://openalex.org/W2281461321","https://openalex.org/W3165120182","https://openalex.org/W4408027528"],"abstract_inverted_index":{"Objectives":[0],"IKZF1":[1,47,158],"and":[2,8,29,37,48,64,68,77,81,122,132,139,160,173,182,191,229,243],"IKZF3":[3,49,161],"(encoding":[4],"transcription":[5],"factors":[6],"Ikaros":[7,28,67,172],"Aiolos)":[9],"are":[10],"susceptibility":[11],"loci":[12],"for":[13,91,249],"systemic":[14],"lupus":[15],"erythematosus":[16],"(SLE).":[17],"The":[18],"pharmacology":[19],"of":[20,105,200,214,241,252],"iberdomide":[21,106,188,201,242],"(CC-220),":[22],"a":[23,39,102],"cereblon":[24],"(CRBN)":[25],"modulator":[26],"targeting":[27],"Aiolos,":[30],"was":[31,52,135],"studied":[32],"in":[33,38,54,86,142,177,204],"SLE":[34,63,87,150,185],"patient":[35,151],"cells":[36,58,121,181],"phase":[40],"1":[41],"healthy":[42,65,97,167,205],"volunteer":[43],"study.":[44],"Methods":[45],"CRBN,":[46],"gene":[50],"expression":[51],"measured":[53,73,85,126],"peripheral":[55],"blood":[56,147],"mononuclear":[57],"(PBMC)":[59],"from":[60],"patients":[61],"with":[62,94,137,166],"volunteers.":[66,168],"Aiolos":[69,124,174,209],"protein":[70,175],"levels":[71,164,176],"were":[72,84,99,125],"by":[74,127],"Western":[75],"blot":[76],"flow":[78,128],"cytometry.":[79,129],"Anti-dsDNA":[80],"anti-phospholipid":[82,192],"autoantibodies":[83],"PBMC":[88,186],"cultures":[89],"treated":[90],"7":[92],"days":[93],"iberdomide.":[95],"Fifty-six":[96],"volunteers":[98,206],"randomised":[100],"to":[101],"single":[103],"dose":[104],"(0.03\u20136":[107],"mg,":[108],"n=6":[109],"across":[110],"seven":[111],"cohorts)":[112],"or":[113],"placebo":[114],"(n=2/cohort).":[115],"CD19+":[116,224],"B":[117,178,225],"cells,":[118,179,226],"CD3+":[119],"T":[120,180],"intracellular":[123,208],"Interleukin":[130],"(IL)-2":[131],"IL-1\u03b2":[133,231],"production":[134,194,232],"stimulated":[136],"anti-CD3":[138],"lipopolysaccharide,":[140],"respectively,":[141],"an":[143],"ex":[144,233],"vivo":[145],"whole":[146],"assay.":[148],"Results":[149],"PBMCs":[152],"expressed":[153],"significantly":[154,170],"higher":[155],"CRBN":[156],"(1.5-fold),":[157],"(2.1-fold)":[159],"(4.1-fold)":[162],"mRNA":[163],"compared":[165],"Iberdomide":[169],"reduced":[171],"monocytes.":[183],"In":[184],"cultures,":[187],"inhibited":[189],"anti-dsDNA":[190],"autoantibody":[193],"(IC50":[195],"\u224810":[196],"nM).":[197],"Single":[198],"doses":[199],"(0.3\u20136":[202],"mg)":[203],"decreased":[207,222,230],"(minimum":[210],"mean":[211],"per":[212],"cent":[213],"baseline:":[215],"\u224812%\u201328%":[216],"(B":[217],"cells);":[218],"\u22480%\u201333%":[219],"(T":[220],"cells)),":[221],"absolute":[223],"increased":[227],"IL-2":[228],"vivo.":[234],"Conclusions":[235],"These":[236],"findings":[237],"demonstrate":[238],"pharmacodynamic":[239],"activity":[240],"support":[244],"its":[245],"further":[246],"clinical":[247],"development":[248],"the":[250],"treatment":[251],"SLE.":[253],"Trial":[254],"registration":[255],"number":[256],"NCT01733875;":[257],"Results.":[258]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":14},{"year":2021,"cited_by_count":14},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-09-27T00:00:00"}